1. INTRODUCTION
For people with advanced, non-resectable, or metastatic HER2-positive breast cancer, the recommended therapy regimen includes trastuzumab and capecitabine in addition to Tucatinib. Patients who have had brain metastases or who have been on anti-HER2-based treatment in the past are included in this category [1,2].
It is also approved for use in conjunction with trastuzumab to treat adult patients whose colorectal cancer has advanced after treatment with chemotherapy based on fluoropyrimidines, oxaliplatin, or irinotecan and is either unresectable or has spread. Confirmatory studies are required to confirm and describe the clinical benefit before this indication may be authorized under rapid approval [3].
Some forms of breast cancer are associated with HER-2 gene mutations. Tucatinib blocks the HER-2 gene’s tyrosine kinase enzyme. Tyrosine kinase mutations in the HER-2 gene cause cancer by setting off a chain reaction that increases cell signaling and proliferation. It also blocks essential signaling routes such as PI3K/Akt/mTOR and RAS/RAF/MEK/ERK that promote the growth and longevity of cancer cells. Tucatinib stands out as one of the limited HER2-targeted agents capable of traversing the blood-brain barrier, offering therapeutic benefits for brain metastases in HER2-positive breast cancer. Molecular weight: 480.532 g•mol−1 and chemical formula [4–7]: 6-N-(4,4-dimethyl-5H-1,3-oxazol-2-yl)-4-N-[3-methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]quinazoline-4,6-diamine (Fig. 1).
 | Figure 1. A) Tucatinib and B) Lenvatinib chemical structures. [Click here to view] |
No studies using high performance liquid chromatography (HPLC) with tandem mass spectrometry liquid chromatography tandem mass spectrometry (LC-MSMS) to quantify Tucatinib in human K2EDTA plasma have been published as far as we are aware. For the purpose of quantifying Tucatinib and characterizing its force degradation components utilizing LC-MSMS, there is a single described technique using reverse phase high performance liquid chromatography [8]. Developing and validating a fast, sensitive, and specific LC-MSMS technique for assessing Tucatinib in K2EDTA human plasma was the primary objective of this investigation.
2. MATERIALS AND METHODS
2.1. Reagents and chemicals
The pure Tucatinib and Lenvatinib standards of the purities of 99.81% and 99.87%, respectively, according to chromatographic (HPLC) methods. They are obtained from Shree Icon Lab in Vijayawada, India. Acetonitrile and formic acid that are suitable for HPLC were provided by Finar Chemicals in Ahmedabad, India. HPLC grade water (Millipore, USA) was made by filtering it through a Millipore MilliQ plus device.
2.2. Instrument
Quantum Discovery TSQ mass spectrometry analyzer (Thermo Finnigans, Sans Jose, CA) with an electrospray ionization interface was used for chromatography. It had an autosampling and degassing system and pumps connected to it. The test was done on a Thermo Scientific Hypersil Gold column with a reversed phase (50 × 2.1 mm i.d., 3 μm particle size). The Xcalibur program (version 1.4) was used to handle all the tasks, including gathering and analyzing data.
2.3. Mass and liquid chromatographic system conditions
It was possible to separate the samples using an isocratic mobile phase that was made up of 0.1%HCOOH and acetonitrile in the ratio of 15:85% v/v, with 0.5 ml/min flow rate and a column temperature of 35°C. The settings for tracking multiple reactions were set to 4,000 V spray voltage, 250°C vaporizer, and 350°C capillary temperatures. In multiple reaction monitoring mode, the best MS transitions for Tucatinib were m/z 481.2/382.1 and for Lenvatinib, they were 427.1/56.1 in positive ionization mode.
2.4. Processing of standard solution
The IS (2,000 μg/ml) and the stock solution of Tucatinib (10,000 μg/ml) were processed individually in acetonitrile and subsequently monitored at 5°C in a refrigerating system. To process the standards for working controls for Tucatinib and 1,000 ng/ml for lenvatinib (IS), appropriate dilutions were prepared in acetonitrile. The standard controls for Tucatinib and lenvatinib were executed when required and kept in the refrigerator at a temperature of 2°C–8°C.
2.5. Processing of calibration, and quality control (QC) standards
Linearity control solutions of Tucatinib were processed by introducing 1% quantities of control solutions into plasma blank. The calibration curve was determined to have eight levels. The plasma concentrations of Tucatinib were 1, 3, 30, 180, 520, 1,000, 15,00, and 2,000 ng/ml at the end of the study. The QC levels were similarly executed with plasma blank to get 1, 3, 1,000, and 1,500 ng/ml for the lower limit of quantification (LLOQ) low quality control (LQC), MQC, and high quality control (HQC), respectively. The plasma sample preparation procedure was followed for all contaminated samples.
2.6. Processing of sample solution
30 μl aliquots of each linearity level, Q C sample solutions, and test solutions were combined with 50 μl of an internal working standard solution (1 μg/ml) and shaken vigorously using a vortexer. Following vortex mixing, every solution was rapidly cooled by adding 800 μl of acetonitrile and subjected to mixing for 30 seconds. The mixture was then subjected to centrifugation at 14,000 revolutions per minute for at least 20 minutes at a temperature of 4°C. Following centrifugation, the liquid portion above the sediment was meticulously isolated, and 5 μl portion was introduced into an liquid chromatography-electro spray ionization-mass spectrometry (LC–ESI-MSMS ) instrument for quantification [9].
2.7. Validation of the analytical method
The developed LC–ESI-MSMS technique to assess Tucatinib from biological matrices was validated as per the USFDA bioanalytical method validation guidelines (2018) [10]. The developed procedure was subjected to validation for the parameters selectivity, accuracy, linearity, specificity, matrix effect, extraction recoveries, precision, carryover, dilution integrity, and stability.
2.7.1. Selectivity
The evaluation of selectivity was conducted using the K2EDTA plasma without any substances present. The assessment of selectivity should indicate that there were no notable interferences detected for IS and Tucatinib retention times in blank plasma [11].
2.7.2. Calibration plot and sensitivity
Linearity was detected across eight calibration curves spanning a concentration range of 1 to 2,000 ng/ml for Tucatinib. The linearity plots were generated by graphing peak response fractions of Tucatinib to Lenvatinib against the control solutions of linearity controls [9].
2.7.3. Accuracy and precision
To ensure the method’s precision and accuracy, every QC level was tested six times in three separate batches, both intra-day and inter-day. Precision and accuracy findings within a range of ±15% were deemed acceptable, with the exception of concentrations at LLOQ, for which a tolerance of 20% was deemed acceptable [12].
2.7.4. Matrix effect and extraction recoveries
The extraction recoveries were assessed by computing the fraction of response of QC levels containing known quantities of Tucatinib to the response of Tucatinib introduced at similar quantities to blank plasma after protein precipitation. This analysis was performed three times (n = 3) [13,14]. The matrix impact was assessed by comparing the quantities of Tucatinib dissolved into matrix blank extract to those of pure standards (n = 3).
2.7.5. Dilution linearity
Dilution integrity refers to the evaluation of the diluting process of the sample to ensure that it does not affect the precision and accuracy of assessed concentrations of Tucatinib. The solutions diluted were tested and their precision and accuracy were evaluated to expected findings. Results that fell within a range of ±15% were deemed to be satisfactory in terms of both accuracy and precision [15–18].
2.8. Stability
The stability of the human K2EDTA plasma samples was examined by assessing them at two distinct concentration levels of QC samples. This analysis was conducted under various settings, comparing the samples against recently created calibration curves and QC samples. The concentrations of the QC samples were 3.0 and 1,500 ng/ml, with a total of six samples analyzed. The plasma samples underwent storage for a minimum of 6 hours at room temperature, at a temperature of −20°C for ten days, 3 cycles of freezing and thawing, and for 24 hours at a temperature of 4°C in autosampler [18–22].
